Navigation Links
Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today positive results from pre-clinical studies of its TPM-02 dermal drug delivery technology formulated with retinoic acid, a leading topical treatment for severe acne and an active ingredient used in anti-aging cosmetics.

The proof of concept studies showed a three-fold increase in the amount of retinoic acid delivered into the skin when formulated with TPM-02 compared to a control formulation. Importantly, there was no retinoic acid detected in the bloodstream. TPM-02's ability to deliver an active ingredient to the dermis, the active layer of the skin, highlights the system's potential use in dermatologic and cosmetic products.

This study builds upon Phosphagenics' successes in delivering drugs, including insulin, through the skin without causing skin irritation, and further demonstrates that the TPM-02 technology can be utilized to deliver and hold an active ingredient in the skin, which is optimal in achieving maximum effectiveness from dermatological and cosmetic products.

"These proof of concept studies demonstrate the adaptability and flexibility of Phosphagenics' delivery technology, and we intend to leverage these results in pursuing opportunities in the dermatological and cosmetic fields," said Dr. Esra Ogru, Executive Vice President R&D at Phosphagenics. "The ability to deliver greater amounts of retinoic acid to the skin will produce more effective products for consumers, which is our objective in the areas of dermatology and cosmetics."

In addition to improving the dermal delivery of retinoic acid, Phosphagenics sees broader applications for its TPM-02 technology with additional pre-clinical studies showing potential in the dermal delivery of other compounds, such as coenzyme Q10 (CoQ10) and omega-3 fatty acids.

About Phosphagenics Limited

Phospha genics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR -- Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics' stock on the "over-the-counter" market.

For more information, please visit Phosphagenics' web site at http://www.phosphagenics.com

CONTACT: Company, Dr. Esra Ogru, Executive Vice President Research &Development, +1-646-706-2155, or Harry Rosen, President and CEO,+1-646-715-3581, both of Phosphagenics Limited; or U.S. Investors andMedia, Brian Ritchie or Evan Smith, of FD, +1-212-850-5600, forPhosphagenics Limited

Web site: http://www.phosphagenics.com/

Ticker Symbol: (NASDAQ-OTCBB:PPGNY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)...  Cardinal Health (NYSE: CAH ) today ... per share (EPS) guidance and providing a preliminary view ... with this morning,s announcement of the planned acquisition of ... businesses. Cardinal Health now believes that fiscal ... the bottom of its previous guidance range of $5.35 ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be a result ... has helped many women become pregnant upon treating their diagnosis. , ... outpatient evaluations. We can provide the necessary information to diagnose and treat ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... expertise for sponsors and CROs to speed clinical development, has released the ... platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting and ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates ... Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
Breaking Medicine News(10 mins):